Evaluation of disintegration time and palatability of mitiglinide-voglibose combined orally disintegrating tablet.

Evaluation of disintegration time and palatability of mitiglinide-voglibose combined orally disintegrating tablet. - Disintegration time and palatability of mitiglinide-voglibose combined orally disintegrating tablet.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026208

Enrollment

Registered

2017-02-20

Start date

2017-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

mitiglinide-voglibose combined orally disintegrating tablet mitiglinide orally disintegrating tablet and voglibose orally disintegrating tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adult(male and female)

Exclusion criteria

Exclusion criteria: 1.clearly taste disorder 2.allegy for drugs 3.pregnant and/or lactating women 4.other who was decided as inadequate by doctor

Design outcomes

Primary

Measure	Time frame
palatability	—

Secondary

Measure	Time frame
disintegrating time	—

Countries

Japan

Contacts

Public ContactAkio Hakamata

Hamamatsu University School of Medicine Department of Clinical Pharmacology and Therapeutics

hakamata@hama-med.ac.jp053-435-2385

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026